Beauty Blend (GHK + KPV)

Beauty Blend is a vendor-crafted peptide mix combining GHK (or its copper form, GHK-Cu) with KPV, marketed together for skin, hair, and anti-inflammatory benefits rather than sold as a single characterized compound. On dosing, reported amounts span 200 mcg to 2 mg, most commonly landing at 2 mg, though most posters don't state a timing or cycling schedule. The honest caveat: there's no FDA-approved indication for this blend, so every human use is off-label or compounded, and the pairing is a vendor formulation rather than a studied protocol.

Data last updated

ClinicalResearchDepthno dataClinicalResearchEfficacyno dataClinicalResearchSideEffectsno dataAnecdotalEfficacyno dataAnecdotalSideEffectsno dataPriceno data

Measured on 0 of 6 axes

Research Evidence

Evidence shape

Beauty Blend, a combination of GHK and KPV, currently lacks any published human clinical evidence. There are no registered trials, completed studies, or mapped indications for this specific formulation in the scientific literature. Because no data exists to support its use, the efficacy and safety profile of this peptide blend remain entirely unverified in human subjects.

Depthhow much
0 registered trials
Breadthhow many areas
0 indications mapped
Qualityhow rigorous
No completed trials

Anecdotal efficacy

Beauty Blend (GHK + KPV) side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

Symptom-relevant clinical or community evidence has not been captured for this peptide yet.

Price

No live vendor pricing captured for this peptide yet.

BEAUTY BLEND (GHK + KPV) dosing & protocol

How BEAUTY BLEND (GHK + KPV) is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols
Typical dose
0
500 µg
1 mg
1.5 mg
2 mg
no dose captured for this tier yet

No structured protocol details captured for this tier yet.

Clinician practice
Doctor & published-protocol guidance
Typical dose
0
500 µg
1 mg
1.5 mg
2 mg
no dose captured for this tier yet

No structured protocol details captured for this tier yet.

Anecdotal
Community-reported real-world use · n = 3
Typical dose
2 mg200 µg – 2 mg
typical
0
500 µg
1 mg
1.5 mg
2 mg
distribution of 5 reported doses · darker = more
Frequency
unspecified
Route
subQ

The typical dose reported is 2 mg subcutaneously, with a range from 200 µg up to 2 mg; no frequency or cycling pattern was specified in the community reports.

3 sources